You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
As COVID-19 continuing in 2021, it is necessary to take preventive measures, to accelerate the speed of research and development of COVID-19 vaccines and drugs, to advocate the innovation of new vaccines technologies, and to build the strength to win this epidemic.
What are the new challenges of Coronavirus prevention and treatment facing the global pandemic from 2019 to 2022? What opportunities and
challenges exist in the small molecule potent drugs? What changes will be made to the vaccine and drug review policy? How to approve the new
vaccines and drugs?
"New star"-mRNA vaccine that quickly developed in COVID-19. How should we break through technical barriers and build industrial chain?
Other novel vaccine: Recombinant vaccines and adjuvants, viral vector vaccines (adenovirus, influenza virus, etc.) for COVID-19 and other indications.
Focusing on Coronavirus and more: VacCon 2022 , sets one main forum, two sub-main forums. It will invite 60+ government regulatory experts, scientists and leading entrepreneurs who specialize in vaccine/ neutralizing antibody/ small molecule novel coronavirus drugs. The theme is "Focusing on technical breakthrough of the novel vaccines in post COVID-19 era", which will discuss the latest clinical development, before project approval and R&D in COVID-19 vaccine and drugs, and the leading practice of innovation and process development of mRNA/recombinant protein/adenovirus vector vaccine under different technical paths. Aiming at effectively promote the transformation and industrialization of vaccines in China and solve the threats of COVID-19 as soon as possible!
To face the challenge of reduced protective efficacy of mutant strains and first-generation vaccines. To analyze new generation of COVID-19 vaccines the policy supervision, neutralizing antibody, R&D approval (broad spectrum, long-acting), clinical development strategies and commercial prospects.
To track the clinical safety and efficacy of existing or post-marketing COVID-19 vaccines, and find the optimal clinical development strategies to enhance the immunity.
To explore the innovation of mRNA, break the technical barriers of delivery, and create a new world of vaccine; learn the best solution of mRNA vaccine and CMC process production, quality control, industrial chain construction and so on.
To obtain the most cutting-edge technology of the new vaccines (recombinant vaccines, virus vector vaccines), and forecast its broad application prospect and transformation potential in indications.
On December 11-12, 2020, the Chinese Society of Biotechnology and Biomap held the COVID-19 Vaccine/Antibody R&D and Industrialization Forum at Crowne Plaza Kunming City Centre. This conference had more than 580 industry elites to attend, 20 sponsors/exhibitors, 24 reports, 3 topics are fascinating. During the Q&A session, the guests' experience and innovative ideas were highly welcomed by the audience.